Clinical effectiveness of intra-arterial chemoradiotherapy for advanced maxillary sinus carcinoma: based on the reports of the head and neck cancer registry of Japan.

Masahiro Hemmi, Daisuke Sano, Daisuke Kawakita, Seiichi Yoshimoto, Megumi Kitayama, Ken-Ichi Nibu, Nobuhiko Oridate

Abstract read

In one paragraph

Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Masahiro HemmiDepartment of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.

Daisuke SanoDepartment of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan. dsano@yokohama-cu.ac.jp.ORCID http://orcid.org/0000-0002-7686-4724

Daisuke KawakitaDepartment of Otorhinolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan.

Seiichi YoshimotoDepartment of Head and Neck Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

Megumi KitayamaClinical Study Support Center, Wakayama Medical University Hospital, 811-1 Kimiidera, Wakayama, Wakayama, 641-8509, Japan.

Ken-Ichi NibuDepartment of Otolaryngology-Head and Neck Surgery, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe City, Hyogo, 650-0017, Japan.

Nobuhiko OridateDepartment of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBased on the results of the JCOG1212 trial, superselective intra-arterial infusion chemoradiotherapy (IA-CRT) has become a standard treatment option for patients with locally advanced maxillary sinus carcinoma (LA-MSC), especially those with T4a disease, in Japan. This study aimed to evaluate the real-world effectiveness of IA-CRT compared with systemic intravenous chemoradiotherapy (IV-CRT) in patients with LA-MSC.

methodsWe retrospectively analyzed data from patients with T3 and T4 N0M0 maxillary sinus carcinoma who were treated with IA-CRT or IV-CRT between 2011 and 2017, using data from the Head and Neck Cancer Registry of Japan. The primary endpoint was the 5-year local control rate (LCR), and the secondary endpoints were overall survival (OS) and progression-free survival (PFS). Survival analyses were performed using inverse probability of treatment weighting (IPTW) adjustment.

resultsAmong 1,329 registered patients, 507 received definitive chemoradiotherapy as initial treatment, including 373 patients treated with IA-CRT (median follow-up, 46 months) and 134 treated with IV-CRT (median follow-up, 31 months). After IPTW adjustment, the 5-year LCR was significantly higher in the IA-CRT group than in the IV-CRT group (67.0% vs. 46.0%; hazard ratio, 0.61; 95% confidence interval, 0.44-0.84; p = 0.0023). OS and PFS showed no significant differences between the two groups.

conclusionsIA-CRT was associated with improved local control compared with IV-CRT in patients with LA-MSC. Although its impact on survival outcomes remains uncertain, these findings provide real-world evidence that complements the results of the JCOG1212 trial and inform treatment selection in routine clinical practice.

Indexed as

ChemoradiotherapyHead and Neck NeoplasmsMaxillary Sinus NeoplasmsAdultAgedAged, 80 and overFemaleHumansInfusions, Intra-ArterialJapanMaleMiddle AgedProgression-Free SurvivalRegistriesRetrospective StudiesTreatment OutcomeIntra-arterial chemoradiotherapyInverse probability of treatment weightingMaxillary sinus carcinomaReal-world data

Identifiers

PMID42192044

DOI10.1007/s10147-026-03070-7

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.